** Compass Pathways CMPS.O shares up 2.8% premarket at $8.69 after $150 mln follow-on offering priced

** UK-based biotech late Weds sold 18.75 mln American depositary shares, including 1.25 mln pre-funded warrants, at $8

** Co intends to use net offering proceeds to fund ongoing COMP005 and COMP006 Phase 3 trials, Phase 2b/3 trial of COMP360 in post-traumatic stress disorder, among other purposes

** CMPS shares on Tues soared 31% after co said its psilocybin-based therapy, COMP360, eased depression symptoms in late-stage trial, as it aims to win approval for the first classic psychedelic treatment in the US

** Shares on Weds rose ~11% to close at $8.45

** Jefferies, TD Cowen, Cantor Fitzgerald and Stifel joint bookrunners for the offering

** Through Weds, CMPS shares up about 90% over the past 12 months

** Avg rating of 11 analysts is "buy"; median PT $20, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))